Mahajan Sukrit, Schmidt Mirko H H, Schumann Ulrike
Institute of Anatomy, Medical Faculty Carl Gustav Carus, Technische Universität Dresden School of Medicine, Fetscherstr 74, 01307 Dresden, Germany.
Cancers (Basel). 2023 Mar 28;15(7):2024. doi: 10.3390/cancers15072024.
Immune cells constitute a major part of the tumor microenvironment, thereby playing an important role in regulating tumor development. They interact with tumor cells, resulting in the suppression or promotion of glioma development. Therefore, in recent years, scientists have focused on immunotherapy that involves enhancing the immune response to fight the battle against cancer more effectively. While it has shown success against different cancer types, immunotherapy faces major roadblocks in glioma treatment. These involve the blood brain barrier, tumor heterogeneity and an immunosuppressive glioma microenvironment, among other factors. Additionally, the interaction of the peripheral immune system with the central nervous system provides another challenge for immunotherapeutic regimens. For modulating different immune cell populations to counter glioma cells, it is important to expand our knowledge about their role within the glioma microenvironment; therefore, herein, we review the different immune cell populations found in the glioma microenvironment and navigate through the various shortcomings of current immunotherapies for glioma. We conclude by providing an insight into ongoing pre-clinical and clinical trials for glioma therapies.
免疫细胞构成肿瘤微环境的主要部分,从而在调节肿瘤发展中发挥重要作用。它们与肿瘤细胞相互作用,导致胶质瘤发展受到抑制或促进。因此,近年来,科学家们专注于免疫疗法,即通过增强免疫反应来更有效地对抗癌症。虽然免疫疗法已在不同类型癌症的治疗中取得成功,但在胶质瘤治疗中面临重大障碍。这些障碍包括血脑屏障、肿瘤异质性和免疫抑制性胶质瘤微环境等因素。此外,外周免疫系统与中枢神经系统的相互作用给免疫治疗方案带来了另一个挑战。为了调节不同的免疫细胞群体来对抗胶质瘤细胞,扩大我们对它们在胶质瘤微环境中作用的认识很重要;因此,在本文中,我们综述了在胶质瘤微环境中发现的不同免疫细胞群体,并探讨了当前胶质瘤免疫疗法的各种缺点。我们通过深入了解正在进行的胶质瘤治疗临床前和临床试验来得出结论。